Logo image of FTRE

FORTREA HOLDINGS INC (FTRE) Stock Fundamental Analysis

NASDAQ:FTRE - Nasdaq - US34965K1079 - Common Stock - Currency: USD

4.78  -0.22 (-4.4%)

After market: 4.78 0 (0%)

Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to FTRE. FTRE was compared to 55 industry peers in the Life Sciences Tools & Services industry. Both the profitability and financial health of FTRE have multiple concerns. FTRE is valued quite cheap, but it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

FTRE had positive earnings in the past year.
FTRE had a positive operating cash flow in the past year.
In multiple years FTRE reported negative net income over the last 5 years.
Each year in the past 5 years FTRE had a positive operating cash flow.
FTRE Yearly Net Income VS EBIT VS OCF VS FCFFTRE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2020 2021 2022 2023 2024 0 200M -200M

1.2 Ratios

With a Return On Assets value of -9.18%, FTRE perfoms like the industry average, outperforming 58.18% of the companies in the same industry.
FTRE's Return On Equity of -24.11% is in line compared to the rest of the industry. FTRE outperforms 47.27% of its industry peers.
Industry RankSector Rank
ROA -9.18%
ROE -24.11%
ROIC N/A
ROA(3y)-1.75%
ROA(5y)-2.26%
ROE(3y)-6.6%
ROE(5y)-5.54%
ROIC(3y)N/A
ROIC(5y)N/A
FTRE Yearly ROA, ROE, ROICFTRE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2020 2021 2022 2023 2024 0 -10 -20

1.3 Margins

The Gross Margin of FTRE (19.81%) is worse than 81.82% of its industry peers.
In the last couple of years the Gross Margin of FTRE has remained more or less at the same level.
The Profit Margin and Operating Margin are not available for FTRE so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 19.81%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.07%
GM growth 5YN/A
FTRE Yearly Profit, Operating, Gross MarginsFTRE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2020 2021 2022 2023 2024 0 10 -10 20

More info and screens

2

2. Health

2.1 Basic Checks

FTRE does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for FTRE has been increased compared to 1 year ago.
The debt/assets ratio for FTRE has been reduced compared to a year ago.
FTRE Yearly Shares OutstandingFTRE Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 2023 2024 20M 40M 60M 80M
FTRE Yearly Total Debt VS Total AssetsFTRE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 2023 2024 1B 2B 3B 4B

2.2 Solvency

FTRE has an Altman-Z score of 0.62. This is a bad value and indicates that FTRE is not financially healthy and even has some risk of bankruptcy.
FTRE has a worse Altman-Z score (0.62) than 67.27% of its industry peers.
FTRE has a debt to FCF ratio of 4.74. This is a neutral value as FTRE would need 4.74 years to pay back of all of its debts.
FTRE has a Debt to FCF ratio of 4.74. This is in the better half of the industry: FTRE outperforms 67.27% of its industry peers.
FTRE has a Debt/Equity ratio of 0.77. This is a neutral value indicating FTRE is somewhat dependend on debt financing.
The Debt to Equity ratio of FTRE (0.77) is worse than 74.55% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.77
Debt/FCF 4.74
Altman-Z 0.62
ROIC/WACCN/A
WACC6.97%
FTRE Yearly LT Debt VS Equity VS FCFFTRE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2020 2021 2022 2023 2024 1B 2B 3B

2.3 Liquidity

A Current Ratio of 1.00 indicates that FTRE may have some problems paying its short term obligations.
FTRE has a Current ratio of 1.00. This is amonst the worse of the industry: FTRE underperforms 85.45% of its industry peers.
FTRE has a Quick Ratio of 1.00. This is a bad value and indicates that FTRE is not financially healthy enough and could expect problems in meeting its short term obligations.
Looking at the Quick ratio, with a value of 1.00, FTRE is doing worse than 78.18% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 1
Quick Ratio 1
FTRE Yearly Current Assets VS Current LiabilitesFTRE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

More info and screens

3

3. Growth

3.1 Past

FTRE shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -1162.07%.
Looking at the last year, FTRE shows a decrease in Revenue. The Revenue has decreased by -5.14% in the last year.
Measured over the past years, FTRE shows a decrease in Revenue. The Revenue has been decreasing by -4.10% on average per year.
EPS 1Y (TTM)-1162.07%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%150%
Revenue 1Y (TTM)-5.14%
Revenue growth 3Y-4.1%
Revenue growth 5YN/A
Sales Q2Q%-1.63%

3.2 Future

FTRE is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 50.34% yearly.
The Revenue is expected to grow by 3.13% on average over the next years.
EPS Next Y33.53%
EPS Next 2Y55.88%
EPS Next 3Y61.42%
EPS Next 5Y50.34%
Revenue Next Year-8.16%
Revenue Next 2Y-2.59%
Revenue Next 3Y-0.21%
Revenue Next 5Y3.13%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
FTRE Yearly Revenue VS EstimatesFTRE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 1B 2B 3B 4B
FTRE Yearly EPS VS EstimatesFTRE Yearly EPS VS EstimatesYearly EPS VS Estimates 2023 2024 2025 2026 2027 2028 2029 0.5 1 1.5 2 2.5

More info and screens

8

4. Valuation

4.1 Price/Earnings Ratio

Based on the Price/Earnings ratio of 11.95, the valuation of FTRE can be described as reasonable.
94.55% of the companies in the same industry are more expensive than FTRE, based on the Price/Earnings ratio.
FTRE is valuated cheaply when we compare the Price/Earnings ratio to 24.95, which is the current average of the S&P500 Index.
The Price/Forward Earnings ratio is 5.79, which indicates a rather cheap valuation of FTRE.
Based on the Price/Forward Earnings ratio, FTRE is valued cheaper than 98.18% of the companies in the same industry.
When comparing the Price/Forward Earnings ratio of FTRE to the average of the S&P500 Index (20.99), we can say FTRE is valued rather cheaply.
Industry RankSector Rank
PE 11.95
Fwd PE 5.79
FTRE Price Earnings VS Forward Price EarningsFTRE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30 40

4.2 Price Multiples

FTRE's Price/Free Cash Flow ratio is rather cheap when compared to the industry. FTRE is cheaper than 100.00% of the companies in the same industry.
Industry RankSector Rank
P/FCF 1.82
EV/EBITDA N/A
FTRE Per share dataFTRE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 10 -10 20

4.3 Compensation for Growth

The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
A more expensive valuation may be justified as FTRE's earnings are expected to grow with 61.42% in the coming years.
PEG (NY)0.36
PEG (5Y)N/A
EPS Next 2Y55.88%
EPS Next 3Y61.42%

More info and screens

0

5. Dividend

5.1 Amount

FTRE does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

FORTREA HOLDINGS INC

NASDAQ:FTRE (5/14/2025, 4:20:00 PM)

After market: 4.78 0 (0%)

4.78

-0.22 (-4.4%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)05-12 2025-05-12/bmo
Earnings (Next)08-11 2025-08-11/bmo
Inst Owners106.26%
Inst Owner Change-2.86%
Ins Owners0.32%
Ins Owner Change13.92%
Market Cap432.78M
Analysts51.25
Price Target7.75 (62.13%)
Short Float %9.18%
Short Ratio2.81
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-30.76%
Min EPS beat(2)-51.68%
Max EPS beat(2)-9.84%
EPS beat(4)0
Avg EPS beat(4)-201.22%
Min EPS beat(4)-608.63%
Max EPS beat(4)-9.84%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-2.39%
Min Revenue beat(2)-2.83%
Max Revenue beat(2)-1.96%
Revenue beat(4)0
Avg Revenue beat(4)-6.13%
Min Revenue beat(4)-13.98%
Max Revenue beat(4)-1.96%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-33.33%
PT rev (3m)-64.98%
EPS NQ rev (1m)-42.67%
EPS NQ rev (3m)-137.85%
EPS NY rev (1m)-10.44%
EPS NY rev (3m)-65.6%
Revenue NQ rev (1m)-0.42%
Revenue NQ rev (3m)-8.38%
Revenue NY rev (1m)-0.55%
Revenue NY rev (3m)-9.08%
Valuation
Industry RankSector Rank
PE 11.95
Fwd PE 5.79
P/S 0.16
P/FCF 1.82
P/OCF 1.65
P/B 0.32
P/tB N/A
EV/EBITDA N/A
EPS(TTM)0.4
EY8.37%
EPS(NY)0.83
Fwd EY17.28%
FCF(TTM)2.62
FCFY54.83%
OCF(TTM)2.9
OCFY60.72%
SpS29.78
BVpS15.05
TBVpS-11.09
PEG (NY)0.36
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -9.18%
ROE -24.11%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 19.81%
FCFM 8.8%
ROA(3y)-1.75%
ROA(5y)-2.26%
ROE(3y)-6.6%
ROE(5y)-5.54%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.07%
GM growth 5YN/A
F-Score5
Asset Turnover0.75
Health
Industry RankSector Rank
Debt/Equity 0.77
Debt/FCF 4.74
Debt/EBITDA N/A
Cap/Depr 29.34%
Cap/Sales 0.95%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1
Quick Ratio 1
Altman-Z 0.62
F-Score5
WACC6.97%
ROIC/WACCN/A
Cap/Depr(3y)43.05%
Cap/Depr(5y)33.05%
Cap/Sales(3y)1.37%
Cap/Sales(5y)1.18%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-1162.07%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%150%
EPS Next Y33.53%
EPS Next 2Y55.88%
EPS Next 3Y61.42%
EPS Next 5Y50.34%
Revenue 1Y (TTM)-5.14%
Revenue growth 3Y-4.1%
Revenue growth 5YN/A
Sales Q2Q%-1.63%
Revenue Next Year-8.16%
Revenue Next 2Y-2.59%
Revenue Next 3Y-0.21%
Revenue Next 5Y3.13%
EBIT growth 1Y-227.92%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year4.17%
EBIT Next 3Y11.58%
EBIT Next 5Y12.15%
FCF growth 1Y85.25%
FCF growth 3Y18.31%
FCF growth 5YN/A
OCF growth 1Y56.06%
OCF growth 3Y15.67%
OCF growth 5YN/A